I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 548 425 745 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

2-9-05

signature 1

PATENT Docket No. 532232000500

ESC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Scot W. EBBINGHAUS et al.

Serial No.: 10/645,471

Filing Date: August 20, 2003

For: METHODS FOR REGULATING

TRANSCRIPTION BY TARGETING

QUADRUPLEX DNA

Examiner: J. Fredman

Group Art Unit: 1637

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

The documents listed on the attached Form PTO/SB/08a/b were cited in an International Search Report (copy attached) mailed on December 8, 2004 directed to a counterpart international or foreign application. A certification under 37 C.F.R. § 1.97(e)(1) follows:

I hereby certify that each item of information was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

I his In	formation Disclosure Statement is submitted:				
With	the application; accordingly, no fee or separate requirements are required.				
Befor	e the mailing of a first Office Action after the filing of a Request for Continued				
Exam	nination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97				
(e)(1)	has been provided.				
With	in three months of the application filing date or before mailing of a first Office Action				
on the	e merits; accordingly, no fee or separate requirements are required. However, if				
	cable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.				
After	receipt of a first Office Action on the merits but before mailing of a final Office Action				
or No	otice of Allowance.				
	A fee is required. A check in the amount of is enclosed.				
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to				
	this submission in duplicate.				
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is				
	believed to be due.				
After	mailing of a final Office Action or Notice of Allowance, but before payment of the				
issue	issue fee.				
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the				
	amount of is enclosed.				
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal				
	form (PTO/SB/17 is attached to this submission in duplicate.)				
	With Before Example (e)(1) Within on the applie After or No				

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532232000500. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 2, 2005

Respectfully submitted,

Kate H. Murashige

Registration No.: 29,959

MORRISON & FOERSTER LLP 3811 Valley Centre Drive, Suite 500

San Diego, California 92130

(858) 720-5112

(Rhea Amid)

PTO/SB/21 (04-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

			Application Number	10/645,471
T	RANSMITT <i>A</i>	AL	Filing Date	August 20, 2003
FORM (to be used for all correspondence after initial filing)			First Named Inventor	Scot W. EBBINGHAUS
			Art Unit	1645
(to be ase	eu for an correspondence aner i	muar ming)	Examiner Name	J. Fredman
Total Numbe	r of Pages in This Submissi	ion 6	Attorney Docket Numb	532232000500
	EN	CLOSURES	(Check all that app	oly)
Fee Transi	mittal Form	Drawing(s)		After Allowance communication to Technology Center (TC)
Fee	Attached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences
Amendme	nt/Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final		Petition to Convert to a Provisional Application		Proprietary Information
Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence Address		Status Letter
Extension of Time Request		Terminal Disclaimer		X Other Enclosure(s) (please Identify below):
Express Abandonment Request [Request for Refund		Form PTO/SB/08a/b (1 page + duplicate)
Information Disclosure Statement (3 pages)		CD, Number	r of CD(s)	3 References Return Receipt Postcard
Certified C	opy of Priority			
Response	to Missing Parts/	Remarks		
Resp	e Application oonse to Missing Parts	CUSTOME	R NO. 25225	
, Ll unde	r 37 CFR 1.52 or 1.53			
	SIGNATU	RE OF APPLIC	ANT, ATTORNEY, OF	RAGENT
irm r ndividual name	MORRISON & FOER Kate H. Murashige - 2			
ignature	Kale H. M	mare	·	
ate	February 2 , 2005	()	

Dated: February 9, 2005



stitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known				
Application Number	10/645,471			
Filing Date	August 20, 2003			
First Named Inventor	Scot W. EBBINGHAUS			
Art Unit	1637			
Examiner Name	J. Fredman			
Attorney Docket Number	532232000500			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-5,176,996	01/1993	Hogan et al.	

		FOREIC	ON PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.'	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of ones bostiment	or Relevant Figures Appear	1,

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	2.	Gowan et al., Molecular Pharmacology (2002) 61:1154-1162	
	3.	International Search Report for PCT/US03/26267, mailed on 8 December 2004, 5 pages	
	4.	Mergny et al., Anti-Cancer Drug Design (1999) 14:327-339	

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Date	
Signature Considered	_

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.